Cyclocurcumin, a curcumin derivative, exhibits anticancer, anti-inflammatory, and immune-modulating abilities and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method. It may have a therapeutic potential as
AMP-PCP is an ATP analog and can bind to the Hsp90 N-terminal domain (Kd: 3.8 μM). AMP-PCP binding favors the formation of the active homodimer of Hsp90.